Full video transcriptClick to expand
Auto-generated transcript of @adamvanspanje's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00PT-141, bi-aggle works on blood flow.
- 0:03But this peptide, it appears to work on your brain.
- 0:07PT-141, also known as bremilenotide,
- 0:10is a synthetic peptide developed from melanotent tube.
- 0:14It's being studied for its effects on sexual desire and arousal,
- 0:19especially in those who haven't responded to traditional medications.
- 0:23Unlike bi-aggle, PT-141 doesn't target the vascular system.
- 0:28Instead, it works on the central nervous system,
- 0:31specifically on melanocortin receptors in the brain linked to sexual function.
- 0:37Clinical trials have explored its use in erectile dysfunction
- 0:40and hyperactive sexual desire disorder.
- 0:43Reported benefits include improved sexual satisfaction in both men and women.
- 0:49This video is for educational purposes only.
- 0:52PT-141 is not approved by the TGA for therapeutic use in Australia.
- 0:56Always consult your healthcare provider.
PT-141 and libido: what the clinical data actually shows
Quick answer
PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women, based on two Phase 3 RECONNECT trials published in 2019. It is not TGA-approved in Australia for any indication, meaning clinical use there falls outside standard regulatory approval pathways. Its central nervous system mechanism distinguishes it from PDE5 inhibitors, though this does not make it interchangeable with or superior to existing treatments for erectile dysfunction.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
PT-141 (Bremelanotide) access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For PT-141 and libido: what the clinical data actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
SCENESSE (afamelanotide implant) FDA Prescribing Information
Afamelanotide (an alpha-MSH analog) is the only FDA-approved melanocortin peptide of this class, and only to increase pain-free light exposure in erythropoietic protoporphyria, not for cosmetic tanning.
FDA
Afamelanotide for Erythropoietic Protoporphyria
Randomized placebo-controlled trials (NEJM) behind the afamelanotide approval; this is the legitimate human melanocortin evidence, distinct from unapproved tanning peptides.
PubMed
VYLEESI (bremelanotide injection) FDA Prescribing Information
Bremelanotide (PT-141) is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women; approval is limited to that indication.
FDA
Bremelanotide for Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Pivotal RECONNECT studies: two double-blind placebo-controlled Phase 3 trials (1,267 women) showing improved sexual desire and reduced distress versus placebo.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
PT-141 (Bremelanotide) is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "PT-141 and libido: what the clinical data actually shows" from Adam fitness. We read the clip as a Peptide social video fact-checks claim about PT-141 (Bremelanotide), then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women, based on two Phase 3 RECONNECT trials published in 2019.
The reason this review is not generic is the source wording and the canonical claim label "peptides pt 141 a new path to libido support pt 141 bremelanotide is." In this clip, the useful excerpt is: "PT-141, bi-aggle works on blood flow." That wording changes the review because it points to PT-141 (Bremelanotide) safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against SCENESSE (afamelanotide implant) FDA Prescribing Information (2019), Afamelanotide for Erythropoietic Protoporphyria (2015), and Melanotan II injection resulting in systemic toxicity and rhabdomyolysis (2012), plus the creator's own wording. PT-141 (Bremelanotide) still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women, based on two Phase 3 RECONNECT trials published in 2019.
FormBlends verdict
PT-141 (Bremelanotide) safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the PT-141 (Bremelanotide) guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women, based on two Phase 3 RECONNECT trials published in 2019. It is not TGA-approved in Australia for any indication, meaning clinical use there falls outside standard regulatory approval pathways. Its central nervous system mechanism distinguishes it from PDE5 inhibitors, though this does not make it interchangeable with or superior to existing treatments for erectile dysfunction.
- The FDA approved bremelanotide (Vyleesi) in 2019 specifically for HSDD in premenopausal women, based on the RECONNECT Phase 3 trials (Kingsberg et al., 2019, Obstetrics and Gynecology).
- PT-141 acts on MC3R and MC4R melanocortin receptors in the brain, a genuinely different mechanism from PDE5 inhibitors like sildenafil.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- PT-141 (Bremelanotide) decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the PT-141 (Bremelanotide) guide, cost path, safety notes, and provider review before acting.
Review PT-141 (Bremelanotide)What You'll Learn
- The FDA approved bremelanotide (Vyleesi) in 2019 specifically for HSDD in premenopausal women, based on the RECONNECT Phase 3 trials (Kingsberg et al., 2019, Obstetrics and Gynecology).
- PT-141 acts on MC3R and MC4R melanocortin receptors in the brain, a genuinely different mechanism from PDE5 inhibitors like sildenafil.
- The creator incorrectly names the studied condition as 'hyperactive' sexual desire disorder. The actual indication is hypoactive (low) sexual desire disorder.
- Nausea affected approximately 40 percent of participants in Phase 3 trials. Transient blood pressure increases were also documented and represent a real clinical consideration.
- Evidence for PT-141 in erectile dysfunction exists only at Phase 2 level (Rosen et al., 2004). No regulatory body has approved it for this use.
- PT-141 has no TGA approval in Australia for any condition, meaning compounded versions exist outside standard regulatory oversight.
- Compounded bremelanotide is not equivalent to FDA-approved Vyleesi. Quality, purity, and dosing consistency in compounded products are not subject to the same regulatory scrutiny.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @adamvanspanje actually say?
The core claim here is that PT-141 targets the brain rather than blood vessels, making it distinct from PDE5 inhibitors like sildenafil. The creator says it works on "melanocortin receptors in the brain linked to sexual function" and has been studied for erectile dysfunction and "hyperactive sexual desire disorder." They also note it is not TGA-approved in Australia. That's a reasonable summary of the drug's mechanism and regulatory status, delivered with appropriate caveats.
Worth noting: the creator correctly flags that PT-141 is not approved by Australia's TGA, and tells viewers to consult a healthcare provider. That kind of disclosure is increasingly rare in peptide content on TikTok, and it matters.
Does the science back this up?
Mostly, yes, though the picture is more complicated than a short video can convey. PT-141's central mechanism is reasonably well-established. It is a melanocortin receptor agonist, primarily acting on MC3R and MC4R receptors in the hypothalamus, which are involved in sexual arousal signaling. This is meaningfully different from how sildenafil works.
The FDA approved bremelanotide under the brand name Vyleesi in 2019, specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval was based on two Phase 3 trials: the RECONNECT studies (Kingsberg et al., 2019, Obstetrics and Gynecology). Those trials showed statistically significant improvements in sexual desire and reductions in distress related to low desire. Effect sizes were modest but real.
For erectile dysfunction, the evidence is thinner. Early Phase 2 trials showed promise (Rosen et al., 2004, International Journal of Impotence Research), but PT-141 never received FDA approval for ED. The creator implies ongoing clinical exploration, which is accurate, but framing ED as an established studied indication without noting the lack of approval is a small but meaningful omission.
What did they get wrong (or right)?
The terminology slips are minor but worth flagging. The creator calls it "hyperactive sexual desire disorder," which is not a real diagnostic term. The correct condition studied is hypoactive sexual desire disorder (HSDD), meaning low desire, not excessive desire. That is the opposite of what the word "hyperactive" suggests, and it could genuinely confuse viewers about what this drug is actually approved to treat.
The mechanism description is largely accurate. Saying PT-141 "works on your brain" rather than the vascular system is a fair simplification. The creator gets credit for not overclaiming: no promises of guaranteed results, no dosing information, no claim that it cures anything. That restraint is appropriate given the regulatory and clinical reality.
One genuine gap: the video says nothing about the side effect profile. Nausea affects a significant portion of users in clinical trials, and transient increases in blood pressure were documented in the RECONNECT studies. That is not a trivial omission for a health-oriented video.
What should you actually know?
PT-141 has a real evidence base for HSDD in premenopausal women, grounded in FDA-reviewed Phase 3 data. Its use for erectile dysfunction or male sexual dysfunction more broadly is off-label and supported by earlier, smaller trials only. The compounded versions circulating in peptide clinics are not the same as Vyleesi, and there is no approved regulatory pathway for compounded bremelanotide in Australia.
The TGA has not approved PT-141 for any indication in Australia, which the creator correctly states. That means access is either through a Special Access Scheme application or, more commonly, through compounding pharmacies operating in a regulatory grey zone. If you are considering this, the conversation with your healthcare provider needs to include the source and quality of whatever you are being offered, not just whether it might work.
- Blood pressure effects are real: transient hypertension was reported in trials and is a contraindication concern for some patients.
- Nausea is the most common side effect reported in Phase 3 data, affecting roughly 40 percent of participants at the approved dose.
- The FDA-approved indication is HSDD in premenopausal women only. Other uses are off-label.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Adam fitness · TikTok creator
65.6K views on this video
PT-141: A new path to libido support? PT-141 (Bremelanotide) is a peptide originally derived from Melanotan II. Unlike ED medications that work on blood flow, PT-141 appears to target the brain—specifically melanocortin receptors associated with arousal. ✅ Studied for: – Erectile dysfunction (non-responders to PDE5 inhibitors) – Female sexual arousal disorder – Increased satisfaction & libido in both sexes 📚 Research: – Shadiack et al., 2007, Current Topics in Medicinal Chemistry – PMC5338879 –
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the fda approved bremelanotide (vyleesi) in 2019 specifically for hsdd?
The FDA approved bremelanotide (Vyleesi) in 2019 specifically for HSDD in premenopausal women, based on the RECONNECT Phase 3 trials (Kingsberg et al., 2019, Obstetrics and Gynecology).
What does the video say about pt-141 acts on mc3r?
PT-141 acts on MC3R and MC4R melanocortin receptors in the brain, a genuinely different mechanism from PDE5 inhibitors like sildenafil.
What does the video say about the creator incorrectly names the studied condition as 'hyperactive' sexual?
The creator incorrectly names the studied condition as 'hyperactive' sexual desire disorder. The actual indication is hypoactive (low) sexual desire disorder.
What does the video say about nausea affected approximately 40 percent of participants in phase 3?
Nausea affected approximately 40 percent of participants in Phase 3 trials. Transient blood pressure increases were also documented and represent a real clinical consideration.
What does the video say about evidence for pt-141 in erectile dysfunction exists only at phase?
Evidence for PT-141 in erectile dysfunction exists only at Phase 2 level (Rosen et al., 2004). No regulatory body has approved it for this use.
What does the video say about pt-141 has no tga approval in australia for any condition,?
PT-141 has no TGA approval in Australia for any condition, meaning compounded versions exist outside standard regulatory oversight.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Adam fitness, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.